0.03%他克莫司软膏治疗面部脂溢性皮炎临床疗效观察

Clinical Efficacy of Facial Seborreheic Dermatitis with 0.03% Topical Tacrolimus Ointment

目的探讨外用0.03%他克莫司软膏治疗面部脂溢性皮炎临床疗效和安全性。方法将78例患者随机分成两组,治疗组40例,外用0.03%他克莫司软膏2次/d;对照组38例,外用丁苯羟酸软膏。疗程均为4周。结果治疗组和对照组临床有效率分别为87.50%和60.53%,治疗组疗效优于对照组。治疗组7例局部出现刺激症状,均发生在用药后1周内。他克莫司组不良反应发生率高于丁苯羟酸组,但二者差异无显著性(P>0.05)。结论他克莫司软膏治疗面部脂溢性皮炎安全、有效。

Objective To investigate the clinical efficacy and safety of topical 0.03% tacrolimus ointment for the treatment of patients with facial seborreheic dermatitis. Methods Seventy-eigth patients were treated with topical 0.03% tacrolimus ointment or bufexamac cream twice a day in a randomized trial, and the clinical symptom and sign scores were recorded before and after treatment. Meanwhile the adverse events were observed. Results The effective rates of the two groups were 87. 50% and 60.53% respectively. Tacrolimus （0.03%） ointment was significantly more effective than that of the bufexamac cream in the patients with seborreheic dermatitis. 7 cases （ 17.50% ） were reported to have local burning and itching after the first weeks treatment. the rates of adverse events were higher in tacrolimus groups than that in bufexamac groups, but there were no statistis differences（P 〉 0.05 ）. Conclusions Tacrolimus ointment 0.03% may be a safe and effective treatment option for the patients with facial seborreheic dermatitis.